North America Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031

The North America Diabetic Neuropathy Treatment Market would witness market growth of 6.6% CAGR during the forecast period (2024-2031).

The US market dominated the North America Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $1,993 million by 2031. The Canada market is experiencing a CAGR of 9% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 8.1% during (2024 - 2031).

An area of notable progress in the management of diabetic neuropathy pertains to the creation of innovative pharmacological interventions. Several medications have been approved for this purpose, including anticonvulsants, antidepressants, and opioids.

Additionally, these approaches include physical therapy, occupational therapy, and lifestyle modifications such as diet and exercise. The primary objectives are to enhance muscular strength and flexibility, alleviate pain and discomfort, and elevate the quality of life for those afflicted with diabetic neuropathy.

According to the National Library of Medicine, diabetes mellitus is particularly significant in Mexico, where it ranks as the sixth highest for the number of adults affected, with 12.8 million individuals diagnosed with the disease in 2019. This number is projected to rise significantly, reaching an estimated 22.3 million by the year 2045. The Mexican government implemented a program (El Sistema de Vigilancia Epidemiológica Hospitalaria de Diabetes Mellitus Tipo 2, SVEHDMT2) to monitor hospital attendance by people suffering from type 2 diabetes mellitus.

Free Valuable Insights: The Diabetic Neuropathy Treatment Market is Predict to reach USD 7.4 Billion by 2031, at a CAGR of 7.3%

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• Abbott Laboratories
• Eli Lilly And Company
• Pfizer, Inc.
• Lupin Limited
• Astellas Pharma, Inc.
• Glenmark Pharmaceuticals Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• McKesson Corporation
• GlaxoSmithKline PLC (GSK)

North America Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Others

By Drug Class

• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Antidepressants
• Opioid
• Capsaicin
• Others

By Disorder Type

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

By Country

• US
• Canada
• Mexico
• Rest of North America

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Diabetic Neuropathy Treatment Market, by Distribution Channel
1.4.2 North America Diabetic Neuropathy Treatment Market, by Drug Class
1.4.3 North America Diabetic Neuropathy Treatment Market, by Disorder Type
1.4.4 North America Diabetic Neuropathy Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. North America Diabetic Neuropathy Treatment Market by Distribution Channel
4.1 North America Hospitals Pharmacies Market by Country
4.2 North America Retail Pharmacies Market by Country
4.3 North America Others Market by Country

Chapter 5. North America Diabetic Neuropathy Treatment Market by Drug Class
5.1 North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
5.2 North America Antidepressants Market by Country
5.3 North America Opioid Market by Country
5.4 North America Capsaicin Market by Country
5.5 North America Others Market by Country

Chapter 6. North America Diabetic Neuropathy Treatment Market by Disorder Type
6.1 North America Peripheral Neuropathy Market by Country
6.2 North America Autonomic Neuropathy Market by Country
6.3 North America Proximal Neuropathy Market by Country
6.4 North America Focal Neuropathy Market by Country

Chapter 7. North America Diabetic Neuropathy Treatment Market by Country
7.1 US Diabetic Neuropathy Treatment Market
7.1.1 US Diabetic Neuropathy Treatment Market by Distribution Channel
7.1.2 US Diabetic Neuropathy Treatment Market by Drug Class
7.1.3 US Diabetic Neuropathy Treatment Market by Disorder Type
7.2 Canada Diabetic Neuropathy Treatment Market
7.2.1 Canada Diabetic Neuropathy Treatment Market by Distribution Channel
7.2.2 Canada Diabetic Neuropathy Treatment Market by Drug Class
7.2.3 Canada Diabetic Neuropathy Treatment Market by Disorder Type
7.3 Mexico Diabetic Neuropathy Treatment Market
7.3.1 Mexico Diabetic Neuropathy Treatment Market by Distribution Channel
7.3.2 Mexico Diabetic Neuropathy Treatment Market by Drug Class
7.3.3 Mexico Diabetic Neuropathy Treatment Market by Disorder Type
7.4 Rest of North America Diabetic Neuropathy Treatment Market
7.4.1 Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel
7.4.2 Rest of North America Diabetic Neuropathy Treatment Market by Drug Class
7.4.3 Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type

Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.1.5.2 Trial and Approval:
8.1.6 SWOT Analysis
8.2 Eli Lilly And Company
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Lupin Limited
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 SWOT Analysis
8.5 Astellas Pharma, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Glenmark Pharmaceuticals Limited
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 SWOT Analysis
8.7 Boehringer Ingelheim International GmbH
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional & Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 SWOT Analysis
8.8 Novartis AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 McKesson Corporation
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis

TABLE 1 North America Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 2 North America Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 3 North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 4 North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 5 North America Hospitals Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 6 North America Hospitals Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 7 North America Retail Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 8 North America Retail Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 9 North America Others Market by Country, 2020 - 2023, USD Million
TABLE 10 North America Others Market by Country, 2024 - 2031, USD Million
TABLE 11 North America Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 12 North America Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 13 North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2020 - 2023, USD Million
TABLE 14 North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2024 - 2031, USD Million
TABLE 15 North America Antidepressants Market by Country, 2020 - 2023, USD Million
TABLE 16 North America Antidepressants Market by Country, 2024 - 2031, USD Million
TABLE 17 North America Opioid Market by Country, 2020 - 2023, USD Million
TABLE 18 North America Opioid Market by Country, 2024 - 2031, USD Million
TABLE 19 North America Capsaicin Market by Country, 2020 - 2023, USD Million
TABLE 20 North America Capsaicin Market by Country, 2024 - 2031, USD Million
TABLE 21 North America Others Market by Country, 2020 - 2023, USD Million
TABLE 22 North America Others Market by Country, 2024 - 2031, USD Million
TABLE 23 North America Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 24 North America Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 25 North America Peripheral Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 26 North America Peripheral Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 27 North America Autonomic Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 28 North America Autonomic Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 29 North America Proximal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 30 North America Proximal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 31 North America Focal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 32 North America Focal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 33 North America Diabetic Neuropathy Treatment Market by Country, 2020 - 2023, USD Million
TABLE 34 North America Diabetic Neuropathy Treatment Market by Country, 2024 - 2031, USD Million
TABLE 35 US Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 36 US Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 37 US Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 38 US Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 39 US Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 40 US Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 41 US Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 42 US Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 43 Canada Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 44 Canada Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 45 Canada Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 46 Canada Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 47 Canada Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 48 Canada Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 49 Canada Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 50 Canada Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 51 Mexico Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 52 Mexico Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 53 Mexico Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 54 Mexico Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 55 Mexico Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 56 Mexico Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 57 Mexico Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 58 Mexico Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 59 Rest of North America Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 60 Rest of North America Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 61 Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 62 Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 63 Rest of North America Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 64 Rest of North America Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 65 Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 66 Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 67 Key Information – Abbott Laboratories
TABLE 68 Key Information – Eli Lilly And Company
TABLE 69 Key Information – Pfizer, Inc.
TABLE 70 Key Information – Lupin Limited
TABLE 71 key information – Astellas Pharma, Inc.
TABLE 72 Key Information – Glenmark Pharmaceuticals Limited
TABLE 73 Key Information – Boehringer Ingelheim International GmbH
TABLE 74 Key Information – Novartis AG
TABLE 75 Key Information – McKesson Corporation
TABLE 76 Key Information – GlaxoSmithKline PLC

List of Figures
FIG 1 Methodology for the research
FIG 2 North America Diabetic Neuropathy Treatment Market, 2020 - 2031, USD Million
FIG 3 Key Factors Impacting Diabetic Neuropathy Treatment Market
FIG 4 Porter’s Five Forces Analysis – Diabetic Neuropathy Treatment Market
FIG 5 North America Diabetic Neuropathy Treatment Market share by Distribution Channel, 2023
FIG 6 North America Diabetic Neuropathy Treatment Market share by Distribution Channel, 20231
FIG 7 North America Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2031, USD Million
FIG 8 North America Diabetic Neuropathy Treatment Market share by Drug Class, 2023
FIG 9 North America Diabetic Neuropathy Treatment Market share by Drug Class, 20231
FIG 10 North America Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2031, USD Million
FIG 11 North America Diabetic Neuropathy Treatment Market share by Disorder Type, 2023
FIG 12 North America Diabetic Neuropathy Treatment Market share by Disorder Type, 20231
FIG 13 North America Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2031, USD Million
FIG 14 North America Diabetic Neuropathy Treatment Market share by Country, 2023
FIG 15 North America Diabetic Neuropathy Treatment Market share by Country, 20231
FIG 16 North America Diabetic Neuropathy Treatment Market Country, 2020 - 2031, USD Million
FIG 17 Recent strategies and developments: Abbott Laboratories
FIG 18 SWOT Analysis: Abbott Laboratories
FIG 19 Swot Analysis: Eli Lilly And Company
FIG 20 SWOT Analysis: Pfizer, Inc.
FIG 21 SWOT Analysis: Lupin Limited
FIG 22 SWOT Analysis: Astellas Pharma, Inc.
FIG 23 SWOT Analysis: Glenmark Pharmaceuticals Limited
FIG 24 SWOT Analysis: Boehringer Ingelheim International GmbH
FIG 25 SWOT Analysis: Novartis AG
FIG 26 SWOT Analysis: McKesson Corporation
FIG 27 SWOT Analysis: GlaxoSmithKline PLC